iX Biopharma Ltd. (SGX:42C)

Revenue by Segment

Financials in millions SGD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017	Jun 30, 2016
Specialty Pharmaceuticals	7.07M	5.65M	5.35M	13.92M	1.12M
Specialty Pharmaceuticals Growth	25.07%	5.60%	-61.54%	1143.88%	42.19%
Nutraceutical	1.11M	508.00K	749.00K	617.00K	939.00K
Nutraceutical Growth	118.90%	-32.18%	21.39%	-34.29%	141.39%
Inter-Segment Sales	-415.00K	-202.00K	-189.00K	-146.00K	-313.00K
Total	7.77M	5.96M	5.91M	14.39M	1.75M
Total Growth	30.34%	0.78%	-58.91%	724.64%	77.16%

Revenue by Geography

Financials in millions SGD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017	Jun 30, 2016
Australia	6.66M	5.47M	5.12M	1.37M	786.00K
Australia Growth	21.90%	6.70%	273.05%	74.68%	25.36%
United States of America	140.00K	5.00K	95.00K	12.40M	-
United States of America Growth	2700.00%	-94.74%	-99.23%	-	-
China	647.00K	408.00K	579.00K	521.00K	870.00K
China Growth	58.58%	-29.53%	11.13%	-40.11%	182.47%
Singapore and Others	318.00K	81.00K	-	-	-
Singapore and Others Growth	292.59%	-	-	-	-
Singapore	-	-	117.00K	93.00K	89.00K
Singapore Growth	-	-	25.81%	4.49%	78.00%
Total	7.77M	5.96M	5.91M	14.39M	1.75M
Total Growth	30.34%	0.78%	-58.91%	724.64%	77.16%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jun 30, 2026

Data Sources Report a data error